Preferred Label : Rucaparib Camsylate;
NCIt synonyms : 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one
(7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1); 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt; Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, Compound
with 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one
(1:1);
NCIt definition : The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and
inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3),
with potential chemo/radiosensitizing and antineoplastic activities. Upon administration,
rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair.
This enhances the accumulation of DNA strand breaks, promotes genomic instability
and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of
DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation
therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the
post-translational ADP-ribosylation of nuclear proteins, which induces signaling and
the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair
pathway plays a key role in DNA repair and is dysregulated in a variety of cancer
cell types.;
UNII : 41AX9SJ8KO;
InChIKey : INBJJAFXHQQSRW-STOWLHSFSA-N;
CAS number : 1859053-21-6;
Drug name : Rubraca;
Molecule name : CO-338; CO 338;
NCI Metathesaurus CUI : CL513492;
Origin ID : C131178;
UMLS CUI : C4294472;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_affects_gene_product
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_component_of_chemotherapy_regimen
- is_salt_form_of
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate
---
